2025 ESC Guidelines for the management of myocarditis and pericarditis
The first ESC guideline to cover myocarditis and pericarditis together. It cements colchicine as first-line adjunctive therapy from the very first attack of pericarditis, escalates to interleukin-1 blockade in colchicine-resistant, corticosteroid-dependent recurrence, and defines a biopsy-guided pathway for virus-negative inflammatory cardiomyopathy. The register's trials are grouped by that treatment ladder below.
This guideline cites 7 of the 199 landmark trials in our Cardiology register.
Acute pericarditis — colchicine1
- 2013ICAPCardiology · Inflammatory · Acute pericarditisInvestigation on Colchicine for Acute Pericarditis
Recurrent pericarditis — colchicine & IL-1 blockade4
- 2021RHAPSODYCardiology · Inflammatory · Recurrent pericarditisRilonacept Inhibition of Interleukin-1 Alpha and Beta for Recurrent Pericarditis
- 2016AIRTRIPCardiology · Inflammatory · Recurrent pericarditisAnakinra-Treatment of Recurrent Idiopathic Pericarditis
- 2014CORP-2Cardiology · Inflammatory · Recurrent pericarditisCOlchicine for Recurrent Pericarditis 2 — multiple recurrences
- 2011CORPCardiology · Inflammatory · Recurrent pericarditisCOlchicine for Recurrent Pericarditis
Postpericardiotomy syndrome — prevention1
- 2014COPPS-2Cardiology · Inflammatory · Postpericardiotomy syndromeCOlchicine for Prevention of the Post-Pericardiotomy Syndrome and Post-operative Atrial Fibrillation 2
Myocarditis & inflammatory cardiomyopathy1
- 2009TIMICCardiology · Inflammatory · MyocarditisTailored IMmunosuppression in virus-negative Inflammatory Cardiomyopathy